Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV

Zhan, Xiaoyan, Martin, Louis N., Slobod, Karen S., Coleclough, Chris, Lockey, Timothy D., Brown, Scott A., Stambas, John, Bonsignori, Mattia, Sealy, Robert E., Blanchard, James L. and Hurwitz, Julia L. 2005, Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV, Vaccine, vol. 23, no. 46-47, pp. 5306-5320.

Attached Files
Name Description MIMEType Size Downloads

Title Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV
Author(s) Zhan, Xiaoyan
Martin, Louis N.
Slobod, Karen S.
Coleclough, Chris
Lockey, Timothy D.
Brown, Scott A.
Stambas, John
Bonsignori, Mattia
Sealy, Robert E.
Blanchard, James L.
Hurwitz, Julia L.
Journal name Vaccine
Volume number 23
Issue number 46-47
Start page 5306
End page 5320
Publisher Elsevier Ltd.
Place of publication Guildford, England
Publication date 2005-11-16
ISSN 0264-410X
1873-2518
Keyword(s) HIV-1 vaccine
Pathogenic SHIV
Non-human primate
Envelope cocktail
Summary A central obstacle to the design of a global HIV-1 vaccine is virus diversity. Pathogen diversity is not unique to HIV-1, and has been successfully conquered in other fields by the creation of vaccine cocktails. Here we describe the testing of an HIV-1 envelope cocktail vaccine. Six macaques received the vaccine, delivered by successive immunizations with recombinant DNA, recombinant vaccinia virus and recombinant envelope proteins. Following vaccination, animals developed a diversity of anti-envelope antibody binding and neutralizing activities toward proteins and viruses that were not represented by sequence in the vaccine. T-cells were also elicited, as measured by gamma-interferon production assays with envelope-derived peptide pools. Vaccinated and control animals were then challenged with the heterologous pathogenic SHIV, 89.6P. Vaccinated monkeys experienced significantly lower virus titers and better maintenance of CD4+ T-cells than unvaccinated controls. The B- and T-cell immune responses were far superior post-challenge in the vaccinated group. Four of six vaccinated animals and only one of six control animals survived a 44-week observation period post-challenge. The present report is the first to describe pathogenic SHIV disease control mediated by a heterologous HIV-1 vaccine, devoid of 89.6 or SIV derivatives.
Language eng
Field of Research 110804 Medical Virology
Socio Economic Objective 970111 Expanding Knowledge in the Medical and Health Sciences
HERDC Research category C1.1 Refereed article in a scholarly journal
Copyright notice ┬ęCopyright 2005 Elsevier Ltd All rights reserved.
Persistent URL http://hdl.handle.net/10536/DRO/DU:30028917

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 27 times in TR Web of Science
Scopus Citation Count Cited 28 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 277 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Wed, 26 May 2010, 16:07:24 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.